Ligand Common Stock Total Equity from 2010 to 2025
| LGND Stock | USD 115.67 0.66 0.57% |
Common Stock Total Equity | First Reported 1999-12-31 | Previous Quarter 17 K | Current Value 17 K | Quarterly Volatility 35.3 K |
Check Ligand Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Ligand Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 35.4 M, Interest Expense of 716.7 K or Total Revenue of 101.8 M, as well as many indicators such as Price To Sales Ratio of 9.2, Dividend Yield of 0.42 or PTB Ratio of 1.51. Ligand financial statements analysis is a perfect complement when working with Ligand Pharmaceuticals Valuation or Volatility modules.
Ligand | Common Stock Total Equity |
Latest Ligand Pharmaceuticals' Common Stock Total Equity Growth Pattern
Below is the plot of the Common Stock Total Equity of Ligand Pharmaceuticals Incorporated over the last few years. It is the total value of common stock equity held by shareholders, representing their ownership interest in the company. Ligand Pharmaceuticals' Common Stock Total Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Ligand Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Common Stock Total Equity | 10 Years Trend |
|
Common Stock Total Equity |
| Timeline |
Ligand Common Stock Total Equity Regression Statistics
| Arithmetic Mean | 23,740 | |
| Geometric Mean | 20,560 | |
| Coefficient Of Variation | 86.23 | |
| Mean Deviation | 9,533 | |
| Median | 20,000 | |
| Standard Deviation | 20,471 | |
| Sample Variance | 419.1M | |
| Range | 85.5K | |
| R-Value | (0.51) | |
| Mean Square Error | 332.6M | |
| R-Squared | 0.26 | |
| Significance | 0.04 | |
| Slope | (2,190) | |
| Total Sum of Squares | 6.3B |
Ligand Common Stock Total Equity History
About Ligand Pharmaceuticals Financial Statements
Ligand Pharmaceuticals stakeholders use historical fundamental indicators, such as Ligand Pharmaceuticals' Common Stock Total Equity, to determine how well the company is positioned to perform in the future. Although Ligand Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Ligand Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Ligand Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Ligand Pharmaceuticals Incorporated. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Common Stock Total Equity | 15.3 K | 14.5 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Ligand Pharmaceuticals is a strong investment it is important to analyze Ligand Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ligand Pharmaceuticals' future performance. For an informed investment choice regarding Ligand Stock, refer to the following important reports:Check out the analysis of Ligand Pharmaceuticals Correlation against competitors. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ligand Pharmaceuticals. If investors know Ligand will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ligand Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.032 | Earnings Share 2.49 | Revenue Per Share | Quarterly Revenue Growth 0.576 | Return On Assets |
The market value of Ligand Pharmaceuticals is measured differently than its book value, which is the value of Ligand that is recorded on the company's balance sheet. Investors also form their own opinion of Ligand Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Ligand Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ligand Pharmaceuticals' market value can be influenced by many factors that don't directly affect Ligand Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ligand Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ligand Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ligand Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.